Related Experiment Video
Updated: Jul 24, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Therapy for recurrent malignant glioma in adults
Maciej M Mrugala1, Santosh Kesari, Naren Ramakrishna
1Harvard Medical School, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02114, USA. mmurugala@partners.org
Abstract:
Malignant gliomas are the most common form of primary brain tumors in adults. Although the prognosis remains poor, there has been recent progress in the treatment of these tumors. Standard therapy for patients with this disease will be reviewed, together with more novel approaches such as targeted molecular therapies, angiogenesis inhibitors, immunotherapies, gene therapies and intratumoral therapies.
Insights
Malignant gliomas, common adult brain tumors, have a poor prognosis but are seeing treatment advances. This review covers standard and novel therapies like targeted molecular treatments and immunotherapies.
Area of Science:
- Neuro-oncology
- Cancer Therapeutics
- Clinical Research
Background:
- Malignant gliomas represent the most frequent primary brain tumors in adults.
- Despite limited survival rates, recent therapeutic advancements offer new hope.
Purpose of the Study:
- To review current standard treatments for malignant gliomas.
- To explore emerging novel therapeutic strategies for brain tumors.
Main Methods:
- Literature review of standard and experimental therapies.
- Synthesis of information on targeted molecular therapies, angiogenesis inhibitors, immunotherapies, gene therapies, and intratumoral therapies.
Main Results:
- Standard therapy protocols are outlined.
- Novel approaches including targeted therapies, angiogenesis inhibitors, immunotherapies, gene therapies, and intratumoral treatments are discussed.
Conclusions:
- While prognosis remains challenging, a range of innovative treatments are being investigated for malignant gliomas.
- The integration of novel therapies alongside standard care may improve outcomes for patients with primary brain tumors.
